ClinicalTrials.gg
RecruitingNCT06114108salVageUpdated Nov 19, 2026

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients

An interventional study of Systemic anticancer therapy and Surgery in Non-small Cell Lung Cancer (NSCLC) and Stage IV, sponsored by Swiss Cancer Institute. Recruiting at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Swiss Cancer Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Nov 19, 2026Start date movedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland — 42 open to participants now, 67 under way, 33 of them phase 3. Carcinoma, Non-Small-Cell Lung · Switzerland.

Planned enrollment
112th of 173
128 · median 290
Started
2024
with 10 others
No phase
6 of 186
4 open now
Primary completion
2027-11
later than 29 of 66 live
Registered
148th of 186
by date
Lead sponsor
8 of 186
Swiss Cancer Institute

Among the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, this one is the 112th largest by planned enrollment of the 173 interventional ones that give a count, is one of 11 that started in 2024, is one of 6 with no phase, reaches primary completion later than 29 of the 66 other live ones, and was the 148th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

42 of the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, or all of them as a file.
02

Study summary

Most patients are already at an advanced stage when they are diagnosed with lung cancer, meaning the cancer has already spread outside the lungs and formed metastases. The current standard of care at this stage is systemic anticancer therapy, such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. This study aims to find out whether it is better if, after a good response to standard therapy, the remaining main tumor and metastases are additionally treated by surgery and/or radiotherapy.

Read the detailed description

This study aims to find out whether, after a good response to standard therapy, it is better if the main tumor and all remaining metastases are additionally treated by surgery and/or radiotherapy. This intervention is called local ablative therapy (LAT). There is evidence that LAT may prolong the time to cancer progression (progression-free survival, PFS) or lead to longer survival. Currently, patients who respond to initial standard therapy are not routinely offered LAT. If the results are positive, this could change the current standard of practice.

The benefit of a therapy is not determined by PFS or survival alone, but also by its impact on quality of life. Side effects, pain, fatigue, nausea or long hospital stays can reduce the benefit from the patient's point of view. Quality of life, assessed with patient-reported outcome measures (PROMs), is therefore a co-primary endpoint, tested hierarchically after PFS.

All patients first receive 3 cycles or 3 months of standard first-line systemic therapy; a 4th bridging cycle is allowed until randomization. Restaging with contrast-enhanced (FDG-PET-)CT and brain MRI is performed 7 to 28 days after the last treatment cycle. Patients with partial response or stable disease and an (induced) oligometastatic or oligopersistent state are randomized 1:1, using minimization, to LAT plus standard systemic therapy or to standard systemic therapy alone. Minimization factors are country, targeted therapy (yes/no), response to first-line therapy, and definitive local treatment of brain metastases before inclusion (yes/no).

The study will enroll 128 patients at Swiss and international hospitals. Each patient is followed for at least 24 months after randomization.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
  • Stage IV

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Local consolidative treatment (LAT)
  • patient-reported outcome measures (PROMs)
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial. The inclusion criteria apply irrespective of the tumor burden at the time of primary diagnosis, before initiation of systemic therapy. Treatment of upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.

  • Adults (18 years or older)
  • Tissue-confirmed, pre-treatment clinical stage IV NSCLC
  • performance status ≤ 1
  • Patients responding after 3 cycles (a 4th bridging cycle up until randomization is allowed) or 3 months of first-line standard-of-care systemic therapy with partial response (PR) or stable disease (SD) in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC, defined as a maximum of 5 residual extracranial distant
  • Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases, as long as they are amenable to radiotherapy or surgery
  • The primary tumor and all oligopersistent metastases must be amenable to radical LAT (surgery and/or radiotherapy)
  • Patients of reproductive age agree to use double during the study
  • Patient is able to understand trial procedures and is able and willing to adhere to them, as confirmed by signature

Exclusion criteria

Exclusion Criteria:

The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:

  • Serious concomitant disorder that would compromise patient safety during LAT
  • Unresolved complications from initial systemic anticancer treatment higher than grade 2
  • locations not measurable by reproducible imaging techniques, such as malignant ascites, malignant pleural or pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses or organomegaly identified by physical examination, or
  • Women who are pregnant or breastfeeding
  • Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board decide on participation on an individual basis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Interventional Arm: Local ablative therapy (LAT) plus systemic therapy

    All patients receive standard first-line systemic therapy according to the molecular analysis of the diagnostic biopsy, per the standard of the treating center. After randomization, patients additionally undergo LAT of the primary tumor and all measurable residual metastases (except PET-negative bone metastases): complete surgical resection of the primary tumor with mediastinal lymph node sampling and/or radical radiotherapy (preferably stereotactic body radiotherapy, SBRT), and surgery and/or SBRT of the metastases. The first LAT is performed within 1 to 35 days after randomization. Choice and sequence of LAT (primary tumor versus metastases) are decided by the local multidisciplinary tumor board (MDT) after interdisciplinary counseling of the patient. Systemic anticancer therapy then continues as standard of care: chemotherapy, chemo-immunotherapy or immunotherapy restarts at the earliest 14 days after LAT; targeted therapy continues throughout.

    Other: Systemic anticancer therapy · Other: Surgery · Radiation: Radiotherapy

  • Active comparator
    Control Arm: Systemic therapy alone

    Patients receive systemic anticancer therapy alone (chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted therapy), per the standard of the treating center. Local ablative treatment is not allowed. Assigned interventions: Other: Systemic anticancer therapy

    Other: Systemic anticancer therapy

Interventions

  • OtherSystemic anticancer therapy

    The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.

    Also known as: Systemic therapy

  • OtherSurgery

    Surgery

  • RadiationRadiotherapy

    Radiotherapy

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS): superiority of local ablative therapy (LAT) plus standard of care (SoC) versus SoC alone

    PFS is defined as the time from randomization to first disease progression or death from any cause, analysed by intention-to-treat. Progression is assessed locally by regular clinical examinations and imaging (contrast-enhanced (FDG-PET-)CT of chest and abdomen, and brain MRI as clinically indicated) according to RECIST 1.1 / iRECIST.

    Time frame: up to 24 months after randomization

  2. Quality of life (QoL): non-inferiority of LAT plus SoC versus SoC alone, measured with the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) index score

    The EQ-5D-5L covers five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels from 1 (no problems) to 5 (extreme problems). Index scores are calculated with the German EQ-5D-5L value set. Non-inferiority is shown if the upper limit of the 2-sided 95% confidence interval of the between-group difference lies below the margin of 0.1. QoL is tested only if PFS superiority is shown (hierarchical testing).

    Time frame: 6 months after randomization

Secondary outcomes

  1. EORTC QLQ-C30 Global Health Status/Quality of Life Score

    Global health status/QoL scale of the EORTC QLQ-C30, scored 0-100; higher scores indicate better quality of life. Compared between treatment groups.

    Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization

  2. EORTC QLQ-LC13 Symptom Scale Scores

    Lung cancer-specific symptom scales of the EORTC QLQ-LC13, each scored 0-100; higher scores indicate more symptoms. Compared between treatment groups.

    Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization

  3. EQ-5D-5L Index Score Over Time

    EQ-5D-5L index score calculated with the German valuation algorithm; higher scores indicate better quality of life. Compared between treatment groups.

    Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization

  4. EQ-5D Visual Analogue Scale (EQ VAS) Score

    Self-rated overall health on the EQ VAS of the EQ-5D-5L, scored 0 (worst imaginable health) to 100 (best imaginable health). Compared between treatment groups.

    Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization

  5. FACT-L Total Score

    Functional Assessment of Cancer Therapy - Lung total score, covering physical, social/family, emotional and functional well-being and the lung cancer subscale; range 0-136, higher scores indicate better quality of life. Compared between treatment groups.

    Time frame: at screening and 3, 6, 12, 18 and 24 months after randomization

  6. Agreement Between Quality of Life Reported in the "My Cancer Companion" App and PROM Scores

    Optional use of the mobile app with daily or as frequent as possible data entry, compared with PROMs completed at the scheduled visits.

    Time frame: up to 24 months after randomization

  7. Number of Participants With Grade ≥ 3 Surgical Complications (Clavien-Dindo)

    Participants undergoing surgical resection with at least one major surgical complication of Clavien-Dindo grade ≥ 3, including the name of the event.

    Time frame: up to 24 months after randomization

  8. Number of Participants With Grade ≥ 3 Radiotherapy-Related Adverse Events (CTCAE v5.0)

    Participants receiving radiotherapy with at least one radiotherapy-related adverse event of CTCAE version 5.0 grade ≥ 3, including the name of the event.

    Time frame: up to 24 months after randomization

  9. Number of Participants With Grade ≥ 3 Systemic Therapy-Related Adverse Events (CTCAE v5.0)

    Participants receiving systemic therapy with at least one systemic therapy-related adverse event of CTCAE version 5.0 grade ≥ 3, including the name of the event.

    Time frame: up to 24 months after randomization

  10. Number of Serious Adverse Reactions (SARs)

    Count of serious adverse reactions related to surgery, radiotherapy or systemic therapy per treatment group, compared as a rate ratio (Poisson regression adjusted for the minimization variables).

    Time frame: up to 24 months after randomization

  11. Quality-Adjusted Life Years (QALYs)

    Area under the EQ-5D-5L index score curve across all time points, compared between treatment groups.

    Time frame: from screening until 24 months after randomization

  12. Healthcare Utilization

    Condition-specific healthcare utilization extracted from the electronic patient charts of the enrolling hospital, complemented by patient-reported use of healthcare services elsewhere at each trial visit. Compared between treatment groups.

    Time frame: from signing informed consent until 24 months after randomization

  13. Condition-Specific Healthcare Costs

    From screening up to 24 months after randomization

    Time frame: Condition-specific healthcare costs in Swiss francs (CHF), including the cost of the study intervention, from a Swiss healthcare system perspective, based on hospital accounting data and published Swiss unit costs. Compared between treatment groups.

  14. Incremental Cost-Effectiveness Ratio (ICER) of the LAT Strategy

    Difference in costs divided by difference in QALYs between LAT plus SoC and SoC alone, in CHF per QALY gained. Calculated if neither strategy is dominant.

    Time frame: up to 24 months after randomization

  15. Overall Survival (OS)

    Time from randomization to death from any cause. Date and cause of death are recorded.

    Time frame: From randomization through study completion, up to 48 months

  16. Objective Response Rate of the Primary Tumor

    Percentage of participants with complete or partial response of the primary tumor, assessed locally by contrast-enhanced FDG-PET-CT according to RECIST 1.1 / iRECIST.

    Time frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization

  17. Objective Response Rate of Metastases

    Percentage of participants with complete or partial response of metastases, assessed locally by contrast-enhanced FDG-PET-CT of chest and abdomen and brain MRI according to RECIST 1.1 / iRECIST.

    Time frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2027, 44 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 44 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

Start moved once since we started tracking on Sep 25, 2026: Dec 2023 → Feb 2024, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Nov 2, 2023
StartActual
Feb 19, 2024was Dec 2023
Primary completionEst.
Nov 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 21, 2023→Feb 19, 2024
Nov 19, 2026
Eligibility
6 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • RemovedPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.
  • EditedPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial. The inclusion criteria areapply irrespective fromof the tumor burden at the time of primary diagnosis, before initiation of first -line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.
  • EditedTissue -confirmed, pre-treatment clinical stage IV NSCLC
  • EditedPatients responding after 3 cycles (a 4th bridging cycle up until randomization is allowed) or 3 months of first -line SoCstandard-of-care systemic therapy with partial response (PR) or stable disease (SD) in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC, defined as a maximum of 5 residual extracranial, distant metastases
  • EditedPatients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases, as long as they are amenable forto radiotherapy or surgery.
  • EditedThe primary tumor and all oligopersistent metastases must be amenable forto radical LAT (surgery and/or radiotherapy)
  • EditedPatient is able to understand trial procedures and is able/ and willing to adhere to trial proceduresthem, as confirmed by signature
Exclusion criteria
  • EditedUnresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2
  • EditedMetastatic locations not measurable by reproducible imaging techniques, such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal or organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques,examination, or leptomeningeal carcinomatosis
  • EditedWomen who are pregnant or breast feedingbreastfeeding
  • EditedPatient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board will decide on participation on an individual basis.
Nov 19, 2026
Interventions
Changed Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)→Systemic anticancer therapy. Arm changed Control group: Systemic Therapy→Control Arm: Systemic therapy alone. Arms added: Interventional Arm: Local ablative therapy (LAT) plus systemic therapy; arms removed: Intervention group: Local consolidative treatment (LAT) & Systemic Therapy
Nov 19, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedProgression-Free Survivalfree survival (PFS) l in the Local Ablative Therapy: superiority of local ablative therapy (LAT) arm is superior to Standardplus standard of Carecare (SoC) versus SoC aloneTime frame: up to 24 months after randomization
  • EditedQuality of life (QoL) in the: non-inferiority of LAT arm is non-inferior to the control arm asplus SoC versus SoC alone, measured with the European Quality of LifeEuroQol 5 Dimensions 3 Level5 Levels (EQ-5D-5L) questionnaire-basedindex score at 6 months after randomizationTime frame: 6 months after randomization
Nov 19, 2026
Secondary outcomes
1 edited, 16 added, 4 removed
What changed in the outcomes
  • EditedTo compare quality-adjusted life yearsQuality-Adjusted Life Years (QALYs)Time frame: up to 24 months after randomization → from screening until 24 months after randomization
  • AddedEORTC QLQ-C30 Global Health Status/Quality of Life ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
  • AddedEORTC QLQ-LC13 Symptom Scale ScoresTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
  • AddedEQ-5D-5L Index Score Over TimeTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
  • AddedEQ-5D Visual Analogue Scale (EQ VAS) ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
  • AddedFACT-L Total ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
  • AddedAgreement Between Quality of Life Reported in the "My Cancer Companion" App and PROM ScoresTime frame: up to 24 months after randomization
  • AddedNumber of Participants With Grade ≥ 3 Surgical Complications (Clavien-Dindo)Time frame: up to 24 months after randomization
  • AddedNumber of Participants With Grade ≥ 3 Radiotherapy-Related Adverse Events (CTCAE v5.0)Time frame: up to 24 months after randomization
  • AddedNumber of Participants With Grade ≥ 3 Systemic Therapy-Related Adverse Events (CTCAE v5.0)Time frame: up to 24 months after randomization
  • AddedNumber of Serious Adverse Reactions (SARs)Time frame: up to 24 months after randomization
  • AddedHealthcare UtilizationTime frame: from signing informed consent until 24 months after randomization
  • AddedCondition-Specific Healthcare CostsTime frame: Condition-specific healthcare costs in Swiss francs (CHF), including the cost of the study intervention, from a Swiss healthcare system perspective, based on hospital accounting data and published Swiss unit costs. Compared between treatment groups.
  • AddedIncremental Cost-Effectiveness Ratio (ICER) of the LAT StrategyTime frame: up to 24 months after randomization
  • AddedOverall Survival (OS)Time frame: From randomization through study completion, up to 48 months
  • AddedObjective Response Rate of the Primary TumorTime frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
  • AddedObjective Response Rate of MetastasesTime frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
  • RemovedPatients undergoing LAT maintain Quality of Life (QoL)Time frame: up to 24 months after randomization
  • RemovedTo assess safety and tolerability of the LAT strategy as compared to standard of careTime frame: from randomization until 30 days after last intervention
  • RemovedTo evaluate the economic impact of the LAT approachTime frame: from signing informed consent until 24 months after randomization
  • RemovedTo assess the response of primary tumor and metastases to systemic treatment alone and in combination with LAT (according to (i)RECIST criteria)Time frame: from intervention until 24 month after randomization
Nov 19, 2026
Title
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCLNon-Small Cell Lung Cancer Patients
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Dec 21, 2023→Feb 19, 2024
    Eligibility 6 inclusion criteria edited, 1 removed; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.
    • EditedPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial. The inclusion criteria areapply irrespective fromof the tumor burden at the time of primary diagnosis, before initiation of first -line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.
    • EditedTissue -confirmed, pre-treatment clinical stage IV NSCLC
    • EditedPatients responding after 3 cycles (a 4th bridging cycle up until randomization is allowed) or 3 months of first -line SoCstandard-of-care systemic therapy with partial response (PR) or stable disease (SD) in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC, defined as a maximum of 5 residual extracranial, distant metastases
    • EditedPatients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases, as long as they are amenable forto radiotherapy or surgery.
    • EditedThe primary tumor and all oligopersistent metastases must be amenable forto radical LAT (surgery and/or radiotherapy)
    • EditedPatient is able to understand trial procedures and is able/ and willing to adhere to trial proceduresthem, as confirmed by signature
    Exclusion criteria
    • EditedUnresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2
    • EditedMetastatic locations not measurable by reproducible imaging techniques, such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal or organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques,examination, or leptomeningeal carcinomatosis
    • EditedWomen who are pregnant or breast feedingbreastfeeding
    • EditedPatient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board will decide on participation on an individual basis.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedProgression-Free Survivalfree survival (PFS) l in the Local Ablative Therapy: superiority of local ablative therapy (LAT) arm is superior to Standardplus standard of Carecare (SoC) versus SoC aloneTime frame: up to 24 months after randomization
    • EditedQuality of life (QoL) in the: non-inferiority of LAT arm is non-inferior to the control arm asplus SoC versus SoC alone, measured with the European Quality of LifeEuroQol 5 Dimensions 3 Level5 Levels (EQ-5D-5L) questionnaire-basedindex score at 6 months after randomizationTime frame: 6 months after randomization
    Secondary outcomes 1 edited, 16 added, 4 removed
    What changed in the outcomes
    • EditedTo compare quality-adjusted life yearsQuality-Adjusted Life Years (QALYs)Time frame: up to 24 months after randomization → from screening until 24 months after randomization
    • AddedEORTC QLQ-C30 Global Health Status/Quality of Life ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
    • AddedEORTC QLQ-LC13 Symptom Scale ScoresTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
    • AddedEQ-5D-5L Index Score Over TimeTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
    • AddedEQ-5D Visual Analogue Scale (EQ VAS) ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
    • AddedFACT-L Total ScoreTime frame: at screening and 3, 6, 12, 18 and 24 months after randomization
    • AddedAgreement Between Quality of Life Reported in the "My Cancer Companion" App and PROM ScoresTime frame: up to 24 months after randomization
    • AddedNumber of Participants With Grade ≥ 3 Surgical Complications (Clavien-Dindo)Time frame: up to 24 months after randomization
    • AddedNumber of Participants With Grade ≥ 3 Radiotherapy-Related Adverse Events (CTCAE v5.0)Time frame: up to 24 months after randomization
    • AddedNumber of Participants With Grade ≥ 3 Systemic Therapy-Related Adverse Events (CTCAE v5.0)Time frame: up to 24 months after randomization
    • AddedNumber of Serious Adverse Reactions (SARs)Time frame: up to 24 months after randomization
    • AddedHealthcare UtilizationTime frame: from signing informed consent until 24 months after randomization
    • AddedCondition-Specific Healthcare CostsTime frame: Condition-specific healthcare costs in Swiss francs (CHF), including the cost of the study intervention, from a Swiss healthcare system perspective, based on hospital accounting data and published Swiss unit costs. Compared between treatment groups.
    • AddedIncremental Cost-Effectiveness Ratio (ICER) of the LAT StrategyTime frame: up to 24 months after randomization
    • AddedOverall Survival (OS)Time frame: From randomization through study completion, up to 48 months
    • AddedObjective Response Rate of the Primary TumorTime frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
    • AddedObjective Response Rate of MetastasesTime frame: at screening (restaging after first-line therapy) and 3, 6, 12, 18 and 24 months after randomization
    • RemovedPatients undergoing LAT maintain Quality of Life (QoL)Time frame: up to 24 months after randomization
    • RemovedTo assess safety and tolerability of the LAT strategy as compared to standard of careTime frame: from randomization until 30 days after last intervention
    • RemovedTo evaluate the economic impact of the LAT approachTime frame: from signing informed consent until 24 months after randomization
    • RemovedTo assess the response of primary tumor and metastases to systemic treatment alone and in combination with LAT (according to (i)RECIST criteria)Time frame: from intervention until 24 month after randomization
    Interventions Changed Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)→Systemic anticancer therapy. Arm changed Control group: Systemic Therapy→Control Arm: Systemic therapy alone. Arms added: Interventional Arm: Local ablative therapy (LAT) plus systemic therapy; arms removed: Intervention group: Local consolidative treatment (LAT) & Systemic Therapy
    Title Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCLNon-Small Cell Lung Cancer Patients
    + 4 other changes: verification date, description, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06114108
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Feb 19, 2024
Primary completion
Nov 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Gwendoline Wicki
Contact
trials@swisscancerinstitute.ch
+41 31 389 91 91
Isabelle Schmitt-Opitz, Prof. Dr. med.
study chair · Department of Thoracic Surgery, University Hospital Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion